These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 32500375)

  • 1. Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature.
    Dohrn MF; Auer-Grumbach M; Baron R; Birklein F; Escolano-Lozano F; Geber C; Grether N; Hagenacker T; Hund E; Sachau J; Schilling M; Schmidt J; Schulte-Mattler W; Sommer C; Weiler M; Wunderlich G; Hahn K
    J Neurol; 2021 Oct; 268(10):3610-3625. PubMed ID: 32500375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene therapy options for hereditary transthyretin-related amyloidosis].
    Schilling M
    Nervenarzt; 2022 Jun; 93(6):557-565. PubMed ID: 35419654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
    Carroll A; Dyck PJ; de Carvalho M; Kennerson M; Reilly MM; Kiernan MC; Vucic S
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):668-678. PubMed ID: 35256455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
    Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
    Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.
    Karam C; Mauermann ML; Gonzalez-Duarte A; Kaku MC; Ajroud-Driss S; Brannagan TH; Polydefkis M
    Muscle Nerve; 2024 Mar; 69(3):273-287. PubMed ID: 38174864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 8. Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
    Meléndrez-Balcázar E; Aranda-Vela K; Cervantes-Hernández A; López-Cureño S
    Am J Kidney Dis; 2024 Aug; 84(2):224-231. PubMed ID: 38484868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy.
    Ueda M; Misumi Y; Nomura T; Tasaki M; Yamakawa S; Obayashi K; Yamashita T; Ando Y
    Ann Neurol; 2024 Feb; 95(2):230-236. PubMed ID: 38053464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.
    Alcantara M; Mezei MM; Baker SK; Breiner A; Dhawan P; Fiander A; Fine NM; Hahn C; Katzberg HD; Khayambashi S; Massie R; Matte G; Putko B; Siddiqi Z; Delgado D; Bril V
    Can J Neurol Sci; 2022 Jan; 49(1):7-18. PubMed ID: 33631091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.
    Luigetti M; Antonini G; Di Paolantonio A; Gentile L; Grandis M; Leonardi L; Lozza A; Manganelli F; Mazzeo A; Mussinelli R; My F; Obici L; Maria Pennisi E; Romozzi M; Russo M; Sabatelli M; Salvalaggio A; Tagliapietra M; Tozza S
    Eur J Neurol; 2022 Jul; 29(7):2148-2155. PubMed ID: 35289020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
    Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
    Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.
    Chiaro G; Stancanelli C; Koay S; Vichayanrat E; Sander L; Ingle GT; McNamara P; Carr AS; Wechalekar AD; Whelan CJ; Gillmore JD; Hawkins PN; Reilly MM; Mathias CJ; Iodice V
    Clin Auton Res; 2024 Jun; 34(3):341-352. PubMed ID: 38769233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant.
    Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K
    Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays.
    Kaku MC; Bhadola S; Berk JL; Sanchorawala V; Connors LH; Lau KHV
    Amyloid; 2022 Sep; 29(3):184-189. PubMed ID: 35253562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary transthyretin amyloidosis overview.
    Manganelli F; Fabrizi GM; Luigetti M; Mandich P; Mazzeo A; Pareyson D
    Neurol Sci; 2022 Dec; 43(Suppl 2):595-604. PubMed ID: 33188616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF; Hahn K
    Inn Med (Heidelb); 2023 Sep; 64(9):848-854. PubMed ID: 37555967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuropathy in hereditary transthyretin amyloidosis: A narrative review.
    Tozza S; Severi D; Spina E; Iovino A; Aruta F; Ruggiero L; Dubbioso R; Iodice R; Nolano M; Manganelli F
    J Peripher Nerv Syst; 2021 Jun; 26(2):155-159. PubMed ID: 33960565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.